In turn, we observed that, upon EGFR inhibition, immune cell infiltration was elevated in the TME (Figure 1B–I), confirming previous findings after erlotinib treatment in NSCLC mouse models [15,45]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.